Biomedcode
Priming Drugs for Success

For any drug development process, pre-clinical testing is the first step in obtaining key evidence on the tested compound’s in vivo effectiveness, providing integral-insights that influence decisions saving time and money. Therefore, it is crucial to use precision animal models that closely mimic the complexity of human pathologies. “We are supporting pharmaceutical and biotech companies across the globe to prime their drugs for success by providing custom-tailored quality pre-clinical services,” says Maria C. Denis, Chief Executive Officer at Biomedcode. An innovative contract research organization (CRO), Biomedcode, offers a diverse array of advanced pre-clinical evaluation platforms and services supported by the firm’s highly active R&D program aiming to generate and standardize novel humanized disease models to serve as preclinical tools.
Biomedcode’s highly trained and experienced personnel provides scientific consultation and method development approaches to meet the efficacy and cost-saving targets of drug development projects. “Biomedcode has the expertise, experience and tools to develop custom-tailored novel disease models and standardized methodologies” adds Niki Karagianni, Chief Scientific Officer at Biomedcode.

Biomedcode’s unique portfolio of genetic or induced mouse disease models humanized for TNF, TNFR1, RANKL, IL17A and IL23p19 closely recapitulate the pathology and complexity of human inflammatory diseases such as arthritis, spondyloarthritis, osteoporosis, psoriasis, IBD, multiple sclerosis and others.

“We understand the needs and constraints of clients. We work towards the direction of developing and optimizing new models that can assist companies in the pharma space with their drug development programs,” states Maria C. Denis, CEO of Biomedcode.

We are enabling pharmaceutical and biotech companies across the globe to prime their drugs for success by providing ready-made or custom-tailored high-quality pre-clinical services

Since its inception in 2006 by Professor George Kollias—Biomedcode has provided pre-clinical drug evaluation services to more than 114 pharmaceutical and biotech companies worldwide successfully supporting the development of a large number of biosimilars, novel biologics, small molecule inhibitors and novel technological platforms. Pre-clinical data generated from the firm’s successful contract research projects are incorporated in IND applications for FDA, SFDA and EMEA approval. Starting its journey with preclinical models of arthritis supporting the development of multiple human therapeutics targeting TNF—Biomedcode has built a strong reputation, gaining the trust and respect of renowned clients from pharmaceutical companies worldwide.

Today, Biomedcode strives to be at the forefront of scientific discovery in the field and plans to introduce organoids and microfluidic technology complementing its standardized pre-clinical platforms. “Biomedcode is the ideal partner to offer quality services and customized solutions to the Pharma sector in alignment with its needs for a more efficient and speedier drug development process,” concludes Niki.